- cafead   Sep 13, 2022 at 08:02: PM
via After the FDA delivered bad news to ObsEva in July—saying its highly touted uterine fibroids candidate linzagolix wasn’t fit for an on-time approval—the Swiss company said it would undergo a drastic restructuring.
article source
article source